Clinical Trial Update: Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the long-term safety and efficacy of Imsidolimab (ANB019) in Generalized Pustular Psoriasis was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Pustular Psoriasis

Drugs mentioned

• Imsidolimab (imsidolimab)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Generalized Pustular Psoriasis | Phase 3 | Status: TERMINATED | Results posted: 2026-03-27